Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak.

Recent mumps outbreaks in older vaccinated populations were caused primarily by genotype G viruses, which are phylogenetically distinct from the genotype A vaccine strains used in the countries affected by the outbreaks. This finding suggests that genotype A vaccine strains could have reduced efficacy against heterologous mumps viruses. The remote history of vaccination also suggests that waning immunity could have contributed to susceptibility. To examine these issues, we obtained consecutive serum samples from children at different intervals after vaccination and assayed the ability of these samples to neutralize the genotype A Jeryl Lynn mumps virus vaccine strain and a genotype G wild-type virus obtained during the mumps outbreak that occurred in the United States in 2006. Although the geometric mean neutralizing antibody titers against the genotype G virus were approximately one-half the titers measured against the vaccine strain, and although titers to both viruses decreased with time after vaccination, antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralized the outbreak-associated virus at all time points tested.

[1]  P. Foster,et al.  Detection of a new mumps virus genotype during parotitis epidemic of 2006–2007 in the State of São Paulo, Brazil , 2008, Journal of medical virology.

[2]  I. Julkunen,et al.  Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination. , 2007, The Journal of infectious diseases.

[3]  M. Paunio,et al.  Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  A. Atrasheuskaya,et al.  Mumps vaccine failure investigation in Novosibirsk, Russia, 2002-2004. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[5]  J. Sohn,et al.  Mumps outbreak in a highly vaccinated school population: assessment of secondary vaccine failure using IgG avidity measurements. , 2007, Vaccine.

[6]  Deborah A. Adams,et al.  Summary of notifiable diseases --- United States, 2005. , 2007, MMWR. Morbidity and mortality weekly report.

[7]  N. Andrews,et al.  Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. , 2007, American journal of epidemiology.

[8]  D. Bi,et al.  Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. , 2007, Archives of pediatrics & adolescent medicine.

[9]  N. Andrews,et al.  Vaccine Effectiveness Estimates, 2004–2005 Mumps Outbreak, England , 2007, Emerging infectious diseases.

[10]  Luis E. Lowe,et al.  Two successive outbreaks of mumps in Nova Scotia among vaccinated adolescents and young adults , 2006, Canadian Medical Association Journal.

[11]  S. Rubin,et al.  Serological and phylogenetic evidence of monotypic immune responses to different mumps virus strains. , 2006, Vaccine.

[12]  B. Sartorius,et al.  An outbreak of mumps in Sweden, February-April 2004. , 2005, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[13]  P. Rota,et al.  Proposal for genetic characterisation of wild-type mumps strains: Preliminary standardisation of the nomenclature , 2005, Archives of Virology.

[14]  M. Roelants,et al.  Outbreak of mumps in a vaccinated child population: a question of vaccine failure? , 2004, Vaccine.

[15]  M. St. Claire,et al.  The Two Major Human Metapneumovirus Genetic Lineages Are Highly Related Antigenically, and the Fusion (F) Protein Is a Major Contributor to This Antigenic Relatedness , 2004, Journal of Virology.

[16]  C. Kang,et al.  Regional outbreak of mumps due to genotype H in Korea in 1999 , 2004, Journal of medical virology.

[17]  G. Cilla,et al.  Mumps outbreak in vaccinated children in Gipuzkoa (Basque Country), Spain , 2002, Epidemiology and Infection.

[18]  C. Orvell,et al.  Antigenic relationships between six genotypes of the small hydrophobic protein gene of mumps virus. , 2002, The Journal of general virology.

[19]  Y. Maldonado,et al.  Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. , 2001, The Journal of infectious diseases.

[20]  S. Fischer,et al.  Localization of a new neutralizing epitope on the mumps virus hemagglutinin-neuraminidase protein. , 2001, Virus research.

[21]  C. Orvell,et al.  Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous mumps virus genotype. , 2001, Vaccine.

[22]  O. Heinonen,et al.  Mumps and rubella eliminated from Finland. , 2000, JAMA.

[23]  C. Orvell,et al.  Characterization of three co-circulating genotypes of the small hydrophobic protein gene of mumps virus. , 1998, The Journal of general virology.

[24]  S. Rubin,et al.  Comparison of the Neurovirulence of a Vaccine and a Wild-Type Mumps Virus Strain in the Developing Rat Brain , 1998, Journal of Virology.

[25]  N. Khetsuriani,et al.  Tetanus surveillance--United States, 1995-1997. , 1998, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[26]  S. Reef,et al.  Measles, Mumps, and Rubella - Vaccine Use and Strategies for Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of Mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Vol. 47/No. RR-8. , 1998 .

[27]  C. Orvell,et al.  Characterization of genotype-specific epitopes of the HN protein of mumps virus. , 1997, The Journal of general virology.

[28]  K. Dimock,et al.  Nucleotide sequence analysis of Urabe mumps vaccine strain that caused meningitis in vaccine recipients. , 1991, Vaccine.

[29]  E. Norrby,et al.  Hemagglutinin-neuraminidase (HN) amino acid alterations in neutralization escape mutants of Kilham mumps virus. , 1990, Virus research.

[30]  E. Walsh,et al.  Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity , 1987, Journal of virology.

[31]  E. Norrby,et al.  Antigenic variation of envelope and internal proteins of mumps virus strains detected with monoclonal antibodies. , 1986, The Journal of general virology.

[32]  M. Hilleman,et al.  Follow-Up Surveillance for Antibody in Human Subjects following Live Attenuated Measles, Mumps, and Rubella Virus Vaccines , 1979, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[33]  P. Mortimer Mumps prophylaxis in the light of a new test for antibody. , 1978, British medical journal.

[34]  M. Hilleman,et al.  Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines. , 1978, Pediatrics.

[35]  M. Hilleman,et al.  Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines. , 1975, Pediatrics.

[36]  M. Hilleman,et al.  Persistence of immunity following monovalent and combined live measles, mumps, and rubella virus vaccines. , 1973, Pediatrics.

[37]  F. Ennis,et al.  Immunity to mumps in an institutional epidemic. Correlation of insusceptibility to mumps with serum plaque neutralizing and hemagglutination-inhibiting antibodies. , 1969, The Journal of infectious diseases.

[38]  M. Hilleman,et al.  Live, attenuated mumps-virus vaccine. , 1968, The New England journal of medicine.

[39]  M. Hilleman,et al.  Live attenuated mumps-virus vaccine. IV. Protective efficacy as measured in a field evaluation. , 1967, The New England journal of medicine.

[40]  M. Hilleman,et al.  Live attenuated mumps-virus vaccine. 3. Clinical and serologic aspects in a field evaluation. , 1967, The New England journal of medicine.

[41]  Frank L. Horsfall,et al.  PERSISTENT ANTIGENIC VARIATION OF INFLUENZA A VIRUSES AFTER INCOMPLETE NEUTRALIZATION IN OVO WITH HETEROLOGOUS IMMUNE SERUM , 1950, The Journal of experimental medicine.

[42]  G. Kärber,et al.  Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche , 1931, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.

[43]  F. Averhoff,et al.  Update : Multistate Outbreak of Mumps — United States , January 1 – May 2 , 2006 .

[44]  W. Bellini,et al.  Brief report: update: mumps activity--United States, January 1-October 7, 2006. , 2006, MMWR. Morbidity and mortality weekly report.

[45]  L. Lindquist,et al.  Molecular characterisation of two mumps virus genotypes circulating during an epidemic in Lithuania from 1998 to 2000 , 2002, Archives of Virology.

[46]  J. P. Davis,et al.  Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 1998, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[47]  Samuel L. Groseclose,et al.  Summary of Notifiable Diseases, United States. , 1997 .